Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 7/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 7/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 7/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591067 | 0.93 | ABCC9 (0.42) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL591102 | 0.92 | ABCC9 (0.35) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL590367 | 0.86 | NAMPT (0.41) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL27763636 | 0.81 | HTR6 (0.38) | ABCC9ABCC8KCNJ11KCNJ8HTR6 | |
| SCHEMBL589669 | 0.79 | ABCC9 (0.37) | ABCC9ABCC8KCNJ11KCNJ8KMT2A | |
| SCHEMBL589817 | 0.78 | CPT1A (0.40) | KMT2AMEN1KDM4ENAMPTALDH1A1 | |
| SCHEMBL3513766 | 0.78 | VNN1 (0.35) | ABCC9ABCC8KCNJ11KCNJ8NPY5R | |
| SCHEMBL3512726 | 0.77 | NTRK1 (0.40) | NPY5R | |
| SCHEMBL590715 | 0.76 | HTR6 (0.38) | HTR6KDM4ELMNAALDH1A1 | |
| SCHEMBL17848156 | 0.76 | DYRK1A (0.40) | KMT2AMEN1NPY5RKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | ABCC9 1789/4885ABCC8 2308/4885KCNJ11 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.